Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + regorafenib + arterial perfusion chemotherapy in first-line advanced cholangiocarcinoma
ChiCTR2200058068Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and regorafenib in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Objective response rate and Progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
tislelizumabregorafenib
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2200058068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058068.